Effects of the kynurenine 3-hydroxylase inhibitor Ro 61-8048 after intrastriatal injections on the severity of dystonia in the dtsz mutant

European Journal of Pharmacology

Volumn 586, Issue 1-3, 2008, Pages 156-159

  Hamann, Melanie ^a   Sander, Svenja E ^a   Richter, Angelika ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Basal ganglia; Dyskinesia; Kynurenic acid; Kynurenine hydroxylase; Movement disorder; Striatum

Indexed keywords

3,4 DIMETHOXY N [4 (3 NITROPHENYL) 2 THIAZOLYL]BENZENESULFONAMIDE; 3,4 DIMETHOXY N [4 (3 NITROPHENYL)THIAZOL 2 YL]BENZENESULFONAMIDE; KYNURENIC ACID; KYNURENINE 3 MONOOXYGENASE; OXYGENASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD LEVEL; BRAIN DYSFUNCTION; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DYSKINESIA; DYSTONIA; HAMSTER; LOCOMOTION; MUTANT; NONHUMAN; PRIORITY JOURNAL; TREATMENT RESPONSE;

ANIMALS; CRICETINAE; DYSTONIA; ENZYME INHIBITORS; KYNURENINE 3-MONOOXYGENASE; MICROINJECTIONS; MUTATION; NEOSTRIATUM; SULFONAMIDES; THIAZOLES;

EID: 43549125008     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.02.052     Document Type: Article

References (19)

1. Carpenedo R., Meli E., Peruginelli F., Domenico E., Pellegrini-Giampietro, and Moroni F. Kynurenine 3-mono-oxygenase inhibitors attenuate post-ischemic neuronal death in organotypic hippocampal slice cultures. J. Neurochem. 82 (2002) 1465-1471
2. Carpenedo R., Pittaluga A., Cozzi A., Attucci S., Galli A., Reiteri M., Moroni F., Chiarugi A., and Moroni F. Quinolinic acid formation in immune-activated mice: studies with (m-nitrobenzoyl)-alanine (mNBA) and 3,4-dimethoxy-[N-4-(3-nitrophenyl)thiazol-2-yl]-benzenesulfonamide (Ro 61-8048), two potent and selective inhibitors of kynurenine hydroxylase. Neuropharmacology 38 (1999) 692-698
3. Hamann M., and Richter A. Striatal increase of extracellular dopamine levels during dystonic episodes in a genetic model of paroxysmal dyskinesia. Neurobiol. Dis. 16 (2004) 78-84
4. Hartai Z., Klivenyi P., Janaky T., Penke B., Dux L., and Vecsei L. Peripheral kynurenine metabolism in focal dystonia. Med. Chem. 3 (2007) 285-288
5. Moroni F., Cozzi A., Carpendo R., Cipriani G., Veneroni O., and Izzo E. Kynurenine 3-mono-oxygenase inhibitors reduce glutamate concentration in the extracellular spaces of the basal ganglia but not in those of the cortex or hippocampus. Neuropharmacology 48 (2005) 788-795
6. Németh H., Toldi J., and Vécsei L. Kynurenines, Parkinson's disease and other neurodegenerative disorders: preclinical and clinical studies. J. Neural. Transm. Suppl. 70 (2006) 285-304
7. Rassoulpour A., Wu H.Q., Ferre S., and Schwarcz R. Nanomolar concentrations of kynurenic acid reduce extracellular dopamine levels in the striatum. J. Neurochem. 93 (2005) 762-765
8. Rehders J.H., Löscher W., and Richter A. Evidence for striatal dopaminergic overactivity in paroxysmal dystonia indicated by microinjections in a genetic rodent model. Neuroscience 97 (2000) 267-277
9. Richter A. The genetically dystonic hamster: an animal model of paroxysmal dystonia. In: LeDoux M. (Ed). Animal Models of Movement Disorders (2005), Elsevier Academic Press, San Diego 459-466
10. Richter A., and Hamann M. The kynurenine 3-hydroxylase inhibitor Ro 61-8048 improves dystonia in a genetic model of paroxysmal dyskinesia. Eur. J. Pharmacol. 478 (2003) 47-52
11. Richter A., and Löscher W. Pathophysiology of idiopathic dystonia: findings from genetic animal models. Prog. Neurobiol. 54 (1998) 633-677
12. Richter A., Löscher W., Baran H., and Gramer M. Increased levels of kynurenic acid in brains of genetically dystonic hamsters. Develop. Brain Res. 92 (1996) 111-116
13. Samadi P., Grégoire L., Rassoulpour A., Guidetti P., Izzo E., Schwarcz R., and Bédard P.J. Effect of kynurenine 3-hydroxylase inhibition on the dyskinetic and antiparkinsonian responses to levodopa in parkinsonian monkeys. Mov. Disord. 20 (2005) 792-802
14. sz mutant. Eur. J. Pharmacol. 563 (2007) 102-108
15. Schwarcz R., and Pellicciari R. Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities. J. Pharmacol. Exp. Therap. 303 (2002) 1-10
16. Stone T.W. Kynurenines in the CNS: from endogenous obscurity to therapeutic importance. Prog. Neurobiol. 64 (2001) 185-218
17. Urenjak J., and Obrenovitch T.P. Kynurenine 3-hydroxylase inhibition in rats: effects on extracellular kynurenic acid concentration and N-methyl-d-aspartate-induced depolarization in the striatum. J. Neurochem. 75 (2000) 2427-2433
18. Wu H.Q., Rassoulpour A., and Schwarcz R. Kynurenic acid leads, dopamine follows: a new case of volume transmission in the brain?. J. Neural. Transm. 114 (2007) 33-41
19. Zhuang P., Li Y., and Hallett M. Neuronal activity in the basal ganglia and thalamus in patients with dystonia. Clin. Neurophysiol. 115 (2004) 2542-2557